Resolving Spliceosomal Malfunctions Advances RNA-Based Therapeutics

Zhao Zhang; Shengli Li; Leng Han

doi:10.1016/j.molmed.2019.11.009

Resolving Spliceosomal Malfunctions Advances RNA-Based Therapeutics

Trends Mol Med. 2020 Feb;26(2):135-137. doi: 10.1016/j.molmed.2019.11.009. Epub 2019 Dec 10.

Authors

Zhao Zhang¹, Shengli Li², Leng Han³

Affiliations

¹ Department of Biochemistry and Molecular Biology, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX 77030, USA. Electronic address: zhao.zhang@uth.tmc.edu.
² Department of Biochemistry and Molecular Biology, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
³ Department of Biochemistry and Molecular Biology, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX 77030, USA; Center for Precision Health, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA. Electronic address: leng.han@uth.tmc.edu.

PMID: 31836419
DOI: 10.1016/j.molmed.2019.11.009

Abstract

Spliceosomes comprise small nuclear (sn)RNAs and proteins. Through genome-wide analyses in large-scale tumor samples, recent studies by Shuai et al., Suzuki et al., and Inoue et al. have identified recurrent spliceosomal mutations that induced genome-wide splicing alterations of cancer-related genes to promote malignancy. These discoveries suggest novel RNA-based therapeutics in anticancer treatment.

Keywords: RNA-based therapeutics; alternative splicing; cancer genomics; spliceosomal mutation.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Genome-Wide Association Study / methods
Humans
Mutation / genetics
Neoplasms / genetics
Proteins / genetics
RNA / genetics*
RNA, Small Nuclear / genetics
Spliceosomes / genetics*

Substances

Proteins
RNA, Small Nuclear
RNA